10/773,785

SAS:dsh:amc1 12/26/06 607192.doc PATENT Attorney Reference Number 6863-67727-01 Application Number 10/773,785

Amendments to the Specification

Please replace the paragraph beginning at page 7, lines 1-11, with the following rewritten paragraph:

include imipramine, amitriptyline, nortriptyline, and desipramine. Monoamine oxidase inhibitors (MAOIs) are also used as antidepressants. MAOIs approved for the treatment of depression include phenelzine (Nardil NARDIL®), tranylcypromine (PARNATE® Parnate), and isocarboxazid (MARPLAN® Marplan). Medications that primarily affect the neurotransmitter serotonin, termed selective serotonin reuptake inhibitors (SSRIs), are also used as antidepressants. These include escitalopram HBr (LEXAPRO® Lexapro), fluoxetine (PROZAC® Prozae), sertraline (ZOLOFT® Zoloft), fluvoxamine (LUVOX® Luvox), paroxetine (PAXIL® Paxil), and citalopram (CELEXA Celexa). Additional medication of use affect both norepinephrine and serotonin, for example venlafaxine (Effexor EFFEXOR®) and nefazadone (SERZONE® Serzone), or agents such as phenelzine (Nardil-NARDIL®), tranylcypromine (PARNATE® Parnate), mirtazepine (REMERON® Remeron), nefazodone (SERZONE® Serzone), triazolopyridine (TRAZODONE® trazodone), and bupropion (WELLBUTRIN® Wellbutrin).

Please replace the paragraphs on page 17, lines 8-8 with the following rewritten

paragraph:

Example 1

Patient 1

A 59-year-old Caucasian female with a history of depression for 3 years was treated. Medications included PAXIL® Paxil (20 mg), as prescribed by her psychiatrist. She appeared somewhat depressed at the time of the first office visit. Her glabellar frown lines and forehead lines were treated with 40 i.u. of BOTOXTM (Fig. 4).